Geode Capital Management
EGRX

Geode Capital Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Geode Capital Management’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-105,846
Closed -$395K – 4593
2024
Q3 		$395K Sell
105,846
-2,158
-2% -$10.3K ﹤0.01% 3687
2024
Q2 		$605K Sell
108,004
-123,637
-53% -$538K ﹤0.01% 3498
2024
Q1 		$1.21M Buy
231,641
+6,346
+3% +$34.8K ﹤0.01% 3291
2023
Q4 		$1.18M Buy
225,295
+5,451
+2% +$53.8K ﹤0.01% 3293
2023
Q3 		$3.47M Buy
219,844
+4,850
+2% +$87.1K ﹤0.01% 2821
2023
Q2 		$4.18M Buy
214,994
+11,841
+6% +$281K ﹤0.01% 2785
2023
Q1 		$5.76M Buy
203,153
+2,848
+1% +$84.5K ﹤0.01% 2573
2022
Q4 		$5.85M Buy
200,305
+3,708
+2% +$118K ﹤0.01% 2583
2022
Q3 		$5.19M Buy
196,597
+6,749
+4% +$248K ﹤0.01% 2652
2022
Q2 		$8.43M Sell
189,848
-15,274
-7% -$702K ﹤0.01% 2368
2022
Q1 		$10.2M Buy
205,122
+720
+0.4% +$34.6K ﹤0.01% 2335
2021
Q4 		$10.4M Sell
204,402
-8,247
-4% -$427K ﹤0.01% 2417
2021
Q3 		$11.9M Buy
212,649
+11,191
+6% +$551K ﹤0.01% 2342
2021
Q2 		$8.62M Buy
201,458
+15,311
+8% +$632K ﹤0.01% 2566
2021
Q1 		$7.77M Buy
186,147
+29,198
+19% +$1.36M ﹤0.01% 2530
2020
Q4 		$7.31M Sell
156,949
-2,932
-2% -$137K ﹤0.01% 2376
2020
Q3 		$6.79M Sell
159,881
-6,156
-4% -$269K ﹤0.01% 2209
2020
Q2 		$7.97M Buy
166,037
+11,568
+7% +$577K ﹤0.01% 2066
2020
Q1 		$7.11M Sell
154,469
-6,648
-4% -$334K ﹤0.01% 1942
2019
Q4 		$9.68M Buy
161,117
+2,127
+1% +$127K ﹤0.01% 2036
2019
Q3 		$8.99M Buy
158,990
+2,202
+1% +$124K ﹤0.01% 2012
2019
Q2 		$8.73M Buy
156,788
+5,479
+4% +$286K ﹤0.01% 2049
2019
Q1 		$7.64M Buy
151,309
+19,266
+15% +$857K ﹤0.01% 2075
2018
Q4 		$5.32M Buy
132,043
+12,748
+11% +$657K ﹤0.01% 2186
2018
Q3 		$8.27M Buy
119,295
+17,260
+17% +$1.31M ﹤0.01% 2056
2018
Q2 		$7.72M Buy
102,035
+22,621
+28% +$1.42M ﹤0.01% 2069
2018
Q1 		$4.18M Buy
79,414
+1,794
+2% +$104K ﹤0.01% 2356
2017
Q4 		$4.15M Sell
77,620
-15,876
-17% -$884K ﹤0.01% 2315
2017
Q3 		$5.58M Buy
93,496
+3,741
+4% +$226K ﹤0.01% 2135
2017
Q2 		$7.08M Sell
89,755
-661
-0.7% -$54.1K ﹤0.01% 1891
2017
Q1 		$7.5M Buy
90,416
+19,710
+28% +$1.47M ﹤0.01% 1823
2016
Q4 		$5.61M Buy
70,706
+2,316
+3% +$168K ﹤0.01% 1999
2016
Q3 		$4.79M Buy
68,390
+1,183
+2% +$65.5K ﹤0.01% 2001
2016
Q2 		$2.61M Sell
67,207
-1,226
-2% -$51.1K ﹤0.01% 2311
2016
Q1 		$2.77K Sell
68,433
-1,517
-2% -$96.3K ﹤0.01% 2233
2015
Q4 		$6.2M Buy
69,950
+141
+0.2% +$11.1K ﹤0.01% 1717
2015
Q3 		$5.17M Buy
69,809
+4,569
+7% +$380K ﹤0.01% 1824
2015
Q2 		$5.28M Buy
65,240
+17,228
+36% +$1.12M ﹤0.01% 1852
2015
Q1 		$2.01M Buy
48,012
+17,961
+60% +$510K ﹤0.01% 2437
2014
Q4 		$465K Buy
30,051
+156
+0.5% +$1.99K ﹤0.01% 3229
2014
Q3 		$378K Buy
29,895
+17,794
+147% +$221K ﹤0.01% 3284
2014
Q2 		$173K Sell
12,101
-1,669
-12% -$19K ﹤0.01% 3556
2014
Q1 		$175K Buy
+13,770
New +$187K ﹤0.01% 3525

Other funds holding EGRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
AIC
Archer Investment Corporation Carmel, Indiana $469M AUM 19.1% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Geode Capital Management's EGRX Position: Q4 2024 in Review

Geode Capital Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2024, closing a stake of 105,846 shares — an estimated $395K sold.

Geode Capital Management first reported a position in EGRX in Q1 2014 and held it in 43 quarters. The position peaked at $11.9M in Q3 2021. 9 funds tracked by Wall St. Rank hold EGRX as of Q4 2024.

  • Geode Capital Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2024 after selling out during the quarter.
  • Geode Capital Management sold 105,846 Eagle Pharmaceuticals, Inc. shares in Q4 2024, an estimated $395K.
  • Geode Capital Management first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2014 and held it in 43 quarters.
  • Geode Capital Management's Eagle Pharmaceuticals, Inc. position peaked at $11.9M in Q3 2021.
  • 9 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2024.

Based on Geode Capital Management's 13F filing for Q4 2024, filed 12 Feb 2025.